Ivosidenib package insert

The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Ivosidenib is an isocitrate dehydrogenase-1 (IDH1

31. Xospata (gilteritinib) package insert. Northbrook, IL: Astellas Pharma Inc; November 2025. 32. Perl AE, Altman JK, Cortes J, et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. Tibsovo (ivosidenib) package insert. Cambridge, MA

Enasidenib: Stein EM et al, Blood 2025; Fathi AT et al. JAMA Oncol. 2025; Norsworthy KJ et al. Clin Cancer Res. 2025; FDA package insert. Ivosidenib: DiNardo CD et al. NEJM 2025; Norsworthy KJ et al. Clin Cancer Res. 2025; FDA package insert. Olutasidenib: de Botton S et al. Blood Adv. 2025; FDA package insert.

Ivosidenib, an oral inhibitor of mIDH1, is currently approved in the United States by the Food and Drug Administration (FDA) and by the European Medicines Agency Studies cited in the Voranigo package insert indicated that there was fetal harm in animal models. 7 Given the paucity of published data, it is advised that female patients should

1Eliquis package insert 2 Pradaxa package insert 3Savaysa package insert 4 Xarelto package insert. CrCl should be based on the Cockcroft-Gault formula

View Manufacturers, Suppliers Exporters of Ivosidenib API listed on PharmaCompass.com. List of Ivosidenib Active Pharmaceutical Ingredient (API) suppliers/manufacturers exporters. Please Wait. - Package Insert - Pipette - Polymer - Pre-Filled Syringe - Pump / Spray - Spoon - Syringe Needle - Tube - Vial - Serialization Equipment

1. Tibsovo (ivosidenib) may be used as monotherapy for IDH1-mutation positive recurrent unresectable or metastatic cholangiocarcinoma, that has progressed on at least one prior line Please refer to the FDA label/package insert for details regarding these topics. PROPRIETARY AND CONFIDENTIAL UM ONC_1340 Tibsovo (ivosidenib)_

On day 31 of ivosidenib, her platelet count was 189 10 3 /mcL, and on day 34, a bone marrow biopsy confirmed a complete remission (CR) Ivosidenib [package insert]. Cambridge, MA: Agios Pharmaceuticals, Inc; 2025. [Google Scholar] Other Formats. PDF (838K) Actions. Cite; Collections. Add to Collections.

Jardiance package insert, Steglatro package insert, Inpefa package insert] vs. either agent alone as initial therapy. In all of these trials